Table 5. Multivariate analysis in the training and validation cohorts.
| Training cohort | Validation cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| PFS | OS | PFS | OS | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| eNOS-786 | ||||||||
| CT+CC | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| TT | 10.24 (2.88-36.45) | 0.0003 | 4.98 (1.48-16.69) | 0.009 | 5.87 (1.28-26.99) | 0.023 | 0.56 (0.04-8.29) | 0.677 |
| eNOS VNTR | ||||||||
| 4ab+4aa | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 4bb | 0.83 (0.31-2.21) | 0.703 | 0.46 (0.16-1.29) | 0.141 | 3.31 (0.67-16.31) | 0.141 | 7.04 (0.70-70.73) | 0.097 |
| eNOS+894 | ||||||||
| GT+TT | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| GG | 1.16 (0.48-2.79) | 0.741 | 0.59 (0.21-1.64) | 0.309 | 1.48 (0.44-5.04) | 0.528 | 11.95 (1.15-24.12) | 0.038 |
| eNOS Haplotypes* | ||||||||
| Other | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| HT1/HT1 | 9.76 (3.19-29.85) | <0.0001 | 2.64 (1.10-6.34) | 0.030 | 11.17 (3.71-33.63) | <0.0001 | 7.03 (1.86-26.55) | 0.004 |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
*
HT1 shows the allele T at eNOS-786 and allele 4b at eNOS VNTR. “Other” indicates haplotypes other than the one indicated.